Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Selected Solid Tumors
Interventions: DRUG: BKM120 + MEK162
Sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer